TABLE 2.

Completed Immunotherapy Trials for Metastatic Esophagogastric Cancer

Trial: Phase (Reference)	Treatment	Prior Lines	No. of Patientsa	ORR, %	Median PFS, mo	Median OS, mo	1-Year OS, %
ATTRACTION-2 (Kang 201763)
Phase 3	Nivo 3 mg/kg	≥2	330 (9% GEJ)	11.2	1.6	5.3	26
KEYNOTE-059 (Fuchs 201864)
Phase 2	Pembro	≥2	259 (51% GEJ)	11.6	2.0	5.6	23
			PD-L1–positive, 148	15.5		5.8
			PD-L1–negative, 109	6.4		4.9
CheckMate-032 (Janjigian 201865)
Phase 1/2	Nivo 3 mg/kg	≥2	59 (53% GEJ)	12.0	1.4	6.2	39b
			PD-L1–positive, 16	19.0
			PD-L1–negative, 26	12.0
	Nivo 1 mg/kg + Ipi 3 mg/kg	≥2	49 (39% GEJ)	24.0	1.4	6.9	35
			PD-L1–positive, 10	40.0
			PD-L1–negative, 32	22.0
	Nivo 3 mg/kg + Ipi 1 mg/kg	≥2	52 (48% GEJ)	8.0	1.6	4.8	24
			PD-L1–positive, 13	23.0
			PD-L1–negative, 30	0.0
KEYNOTE-061: Phase 3 (Shitara 201866)	Pembro	1	296 (30% GEJ)	16.0	1.5	9.1	40
			[PD-L1 CPS ≥1, 196]
	Paclitaxel		296 (32% GEJ)	14.0	4.1	8.3	27
			[PD-L1 CPS ≥1, 199]
JAVELIN Gastric 300: Phase 3 (Bang 201867)	Avelumab	≥2	185 (34% GEJ)	2.2	1.4	4.6	NR
			PD-L1–positive, 46	4.3	1.4	4.0
			PD-L1–negative, 111	1.8	1.4	4.6
	Chemo	≥2	186 (26% GEJ)	4.3	2.7	5.0	NR
			PD-L1–positive, 39	5.1	2.8	4.5
			PD-L1–negative, 121	5.0	2.7	5.3
KEYNOTE-181: Phase 3 (Kojima 201968)c	Pembro	1	222	21.5	3.0	9.3	43
			PD-L1 CPS ≥10, 107
	Chemo		PD-L1 CPS ≥10, 115	6.1	2.6	6.7	20

Abbreviations: Chemo, physician’s-choice chemotherapy; CPS, combined positive score; GEJ, gastroesophageal junction; Ipi, ipilimumab; Nivo, nivolumab; NR, not reported; ORR, overall response rate; PD-L1, programmed-death ligand 1; Pembro, pembrolizumab.

^aPercentages of patients who had GEJ tumors are highlighted in bold where values were available.

^bSeven patients had microsatellite instability-high tumors.

^cThe trial included adenocarcinoma and squamous cell carcinoma.